Plasmablastic lymphoma (PBL) and plasmablastic plasma cell myeloma (PCM) have many overlapping characteristics. Clinical correlation can help make the distinction between the two entities. Human immunodeficiency virus- (HIV-) negative PBL is a rare disease, making the diagnosis more challenging. While there is no standard of care for PBL, current recommendations include dose-adjusted EPOCH (etoposide, vincristine, doxorubicin, cyclophosphamide, and prednisone), with or without bortezomib. We report an aggressive case of HIV-negative plasmablastic lymphoma and discuss the challenge in establishing a diagnosis. We review the literature regarding this disease and current recommendations for treatment.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6393929 | PMC |
| http://dx.doi.org/10.1155/2019/2907317 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Plasmablastic Lymphoma Manifesting As Pleural Thickening and Effusion: A Case Report.
Cureus
November 2024
Radiology, The James Cook University Hospital, Middlesbrough, GBR.
Plasmablastic lymphoma (PbL) is a subtype of diffuse large B-cell lymphoma, primarily linked to human immunodeficiency virus (HIV) infection. This case report presents a 34-year-old HIV-positive patient who exhibited unusual signs of pleural thickening and effusion. Initial evaluations, including imaging and pleural fluid analysis, suggested thoracic empyema.
View Article and Find Full Text PDFSpontaneous Regression of Plasmablastic Lymphoma Associated With Methotrexate After Withdrawal.
J Hematol
December 2024
Department of Hematology, Chuno Kosei Hospital, Gifu, Japan.
Plasmablastic lymphoma (PBL) is a malignant lymphoma with poor prognosis that occurs in immunocompromised and elderly patients. We describe the case of a 75-year-old woman with PBL as a methotrexate-associated lymphoproliferative disorder (MTX-LPD). She presented with multiple oral ulcers and mass-like shadows in the lung fields.
View Article and Find Full Text PDFCardiac Tamponade Due to Diffuse Large B-cell Lymphoma/Plasmablastic Lymphoma in an Immunocompetent Patient.
Cureus
November 2024
Internal Medicine, St Mary Medical Center, Langhorne, USA.
Article Synopsis
- * It typically occurs in males and is characterized by extra-nodal masses, often found in the oral cavity or gastrointestinal tract, but a unique case involved a 93-year-old female without HIV showing pericardial effusion instead.
- * Diagnosis of PBL can be challenging due to atypical presentations; thus, awareness, thorough immunohistochemistry, and clinical correlation are critical for accurate identification.
An Update on EBV-related Cutaneous Lymphoproliferative Disorders: a Systematic Review.
Actas Dermosifiliogr
November 2024
Universidad de Zaragoza, Zaragoza, España; Servicio de Anatomía Patológica, Hospital Clínico Universitario Lozano Blesa, Zaragoza, España.
Epstein Barr virus (EBV) positive B lymphoproliferative disorders (LPD) with cutaneous involvement include a series of rare entities that go from indolent processes to aggressive lymphomas. B-cell EBV+ LPD mainly affect immunocompromised patients while T-cell EBV+ LPD are more prevalent in specific geographic regions such as Asia, Central America, and South America. Since the latest WHO-EORTC classification of cutaneous lymphomas in 2018, significant changes have been included in the new classifications of hematological malignancies.
View Article and Find Full Text PDFBCMA CAR-T induces complete and durable remission in plasmablastic lymphoma synchronous transformation of chronic lymphocytic leukemia: Case report and literature review.
Crit Rev Oncol Hematol
January 2025
Department of Myeloma and Lymphoma, Beijing GoBroad Boren Hospital, Beijing 100070, China; Beijing Branch Center of the Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100070, China; Myeloma Research Institute, Beijing GoBroad Boren Hospital, Beijing 100070, China. Electronic address:
Article Synopsis
- Richter transformation poses a continued risk for chronic lymphocytic leukemia (CLL) patients, even with advancements in targeted therapies like Bruton's tyrosine kinase inhibitor, particularly in a reported case of a 61-year-old male who experienced this change post-treatment.
- After stopping ibrutinib during the COVID-19 pandemic, the patient developed a related plasmablastic lymphoma (PBL), diagnosed through histological analysis of a tumor in the supraclavicular area and bone marrow infiltration.
- The patient underwent treatment with a combination of CHP, venetoclax, and brentuximab vedotin, followed by successful BCMA CAR-T cell therapy, resulting in complete remission and highlighting the potential
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!